InspireMD Reports Record Q3 Revenue with U.S. Launch
I'm PortAI, I can summarize articles.
InspireMD reported record Q3 revenue of $2.5 million, a 39% increase year-over-year, following the U.S. launch of its CGuard Prime carotid stent system. The company completed over 100 procedures but faced a net loss of $12.7 million. Despite financial challenges, it raised $58 million in July and received a Buy rating from analysts with a $5.00 price target. However, Spark's AI Analyst rates NSPR as Neutral due to ongoing profitability issues and a bearish technical outlook. InspireMD focuses on stroke prevention with its proprietary technology and is listed on Nasdaq under NSPR.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments